Loading…
Lobbying Spend
—
Filings
257
Firms Hired
7
Active Period
2003–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Priority for Pediatric Cures Act
2026 · third_quarter · Firm: AVENUE SOLUTIONS
Issues related to Pediatric Review Voucher (PRV); H.R. 10359, Priority for Pediatric Cures Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10359
Priority for Pediatric Cures Act
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Issues related to rare pediatric disease and Priority Review Vouchers (PRVs). H.R. 10359, Priority for Pediatric Cures Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 10359
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1968
Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $80,000
Matched citations: S. 891
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: AVENUE SOLUTIONS
Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $80,000
Matched citations: H.R. 1968
Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S. 891, Bipartisan Health Care Act; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (PL 119-4)
Client expense: — · Firm income: $80,000
Matched citations: S. 891
Share the Savings with Seniors Act
2023 · first_quarter · Firm: THE NICKLES GROUP, LLC
Issues involving separate payment for and patient access to non-opioid alternatives. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to prescription drug prices.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
hospital outpatient prospective payment system; S. 586, the Non-Opioids Prevent Addiction in the Nation Act, also known as the NO PAIN Act"; Physician Fee Schedule and value-based purchasing programs; FY 2023 Omnibus legislation
Client expense: — · Firm income: $45,000
Matched citations: S. 586
Issues related to Medicare reimbursement H.R. 3259 (NOPAIN Act)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3259
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: GRAYROBINSON PA
Issues related to Medicare reimbursement. Reimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system. Merit-Based Incentive Payment System quality measures. Monitor H.R.5376, Build Back Better Act, regarding Medicare issues. H.R. 3259, Non-Opioids Prevent Addiction In the Nation Act or the NOPAIN Act, all provisions. H.R.2617, Consolidated Appropriations Act, 2023, provisions related to NOPAIN Act.
Client expense: — · Firm income: $45,000
Matched citations: H.R.2617
Issues related to Medicare reimbursement. Reimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system. Merit-Based Incentive Payment System quality measures. Monitor H.R.5376, Build Back Better Act, regarding Medicare issues. H.R. 3259, Non-Opioids Prevent Addiction In the Nation Act or the NOPAIN Act, all provisions. H.R.2617, Consolidated Appropriations Act, 2023, provisions related to NOPAIN Act.
Client expense: — · Firm income: $45,000
Matched citations: H.R. 3259
Issues related to Medicare reimbursement. Reimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center payment system. Merit-Based Incentive Payment System quality measures. Monitor H.R.5376, Build Back Better Act, regarding Medicare issues. H.R. 3259, Non-Opioids Prevent Addiction In the Nation Act or the NOPAIN Act, all provisions. H.R.2617, Consolidated Appropriations Act, 2023, provisions related to NOPAIN Act.
Client expense: — · Firm income: $45,000
Matched citations: H.R.5376
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: AVENUE SOLUTIONS
S. 586, Non-Opioids Prevent Addiction In the Nation Act; H.R. 2617, Consolidated Appropriations Act, 2023 - inclusion of the NOPAIN Act (S. 586/HR 3259)
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2617
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: AVENUE SOLUTIONS
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; S. 586, Non-Opioids Prevent Addiction In the Nation Act; H.R. 2617, Consolidated Appropriations Act, 2023 - inclusion of the NOPAIN Act (S. 586/HR 3259)
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2617
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; S. 586, Non-Opioids Prevent Addiction In the Nation Act; H.R. 2617, Consolidated Appropriations Act, 2023 - inclusion of the NOPAIN Act (S. 586/HR 3259)
Client expense: — · Firm income: $80,000
Matched citations: HR 3259
S. 586, Non-Opioids Prevent Addiction In the Nation Act; H.R. 2617, Consolidated Appropriations Act, 2023 - inclusion of the NOPAIN Act (S. 586/HR 3259)
Client expense: — · Firm income: $80,000
Matched citations: HR 3259
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; S. 586, Non-Opioids Prevent Addiction In the Nation Act; H.R. 2617, Consolidated Appropriations Act, 2023 - inclusion of the NOPAIN Act (S. 586/HR 3259)
Client expense: — · Firm income: $80,000
Matched citations: S. 586
S. 586, Non-Opioids Prevent Addiction In the Nation Act; H.R. 2617, Consolidated Appropriations Act, 2023 - inclusion of the NOPAIN Act (S. 586/HR 3259)
Client expense: — · Firm income: $80,000
Matched citations: S. 586
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to access to non-opioid alternatives. S. 586 / H.R.3259, Non-Opioids Prevent Addiction In the Nation Act (NOPAIN Act) and issues involving access for patients to non-opioid alternatives. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to prescription drug prices.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 2617
H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to access to non-opioid alternatives. S. 586 / H.R.3259, Non-Opioids Prevent Addiction In the Nation Act (NOPAIN Act) and issues involving access for patients to non-opioid alternatives. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to prescription drug prices.
Client expense: — · Firm income: $80,000
Matched citations: H.R.3259
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to access to non-opioid alternatives. S. 586 / H.R.3259, Non-Opioids Prevent Addiction In the Nation Act (NOPAIN Act) and issues involving access for patients to non-opioid alternatives. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to prescription drug prices.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 5376
H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to access to non-opioid alternatives. S. 586 / H.R.3259, Non-Opioids Prevent Addiction In the Nation Act (NOPAIN Act) and issues involving access for patients to non-opioid alternatives. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to prescription drug prices.
Client expense: — · Firm income: $80,000
Matched citations: S. 586
hospital outpatient prospective payment system; S. 586, the Non-Opioids Prevent Addiction in the Nation Act, also known as the NO PAIN Act"; Physician Fee Schedule and value-based purchasing programs
Client expense: — · Firm income: $45,000
Matched citations: S. 586
Issues related to medicare reimbursement H.R. 3259 (NOPAIN Act)
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3259
Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System (HOPPS) and Ambulatory Surgical Center (ASC) payment system; S. 586, Non-Opioids Prevent Addiction In the Nation Act
Client expense: — · Firm income: $80,000
Matched citations: S. 586
Source: Senate LDA